[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600400":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":10,"locations":23,"responsibleParty":46,"collaborators":48,"id":52,"slug":10,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"University of Michigan Rogel Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients receive standard care Pluvicto and undergo Lu-177 SPECT\u002FCT scans on study. Patients may also undergo optional 99mTc-SC SPECT\u002FCT scan for bone marrow dosimetry prior to cycle 1. In addition, patients have their medical records reviewed on study.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Non-Interventional Study","Non-interventional study",[9],[20],{"name":21,"affiliation":5,"role":22},"Yuni K Dewaraja","PRINCIPAL_INVESTIGATOR",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"University of Michigan Comprehensive Cancer Center","RECRUITING","Ann Arbor","Michigan","48109","United States","US",{"type":33,"coordinates":34},"Point",[35,36],-83.74088,42.27756,{"lat":36,"lon":35},[39,44],{"name":40,"role":41,"phone":42,"phoneExt":10,"email":43},"James Pool","CONTACT","734-615-7391","jampool@med.umich.edu",{"name":45,"role":22,"phone":10,"phoneExt":10,"email":10},"Yuni K. Dewaraja",{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[49],{"name":50,"class":51},"National Cancer Institute (NCI)","NIH","100600400",false,"NCT07096999","SPECT\u002FCT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy","Inclusion Criteria:\n\n* \\* 177Lu-617 PSMA treatment scheduled for mCRPC\n\n  * Clinically stable as determined by the nuclear medicine clinicians\n  * Male\n  * ≥ 18 years of age\n  * Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed","MALE","18 Years",{"count":60,"type":61},60,"ESTIMATED","OBSERVATIONAL","This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy",[65],"Metastatic Castration-Resistant Prostate Carcinoma",[67,68,69,70,71],"Prostate Cancer","177Lu","PSMA","mCRPC","Radioligand Therapy","2025-07-24",{"date":74,"type":75},"2025-07-31","ACTUAL",{"date":77,"type":75},"2025-01-23",{"date":79,"type":61},"2031-01-23",{"name":5,"class":6},1]